Subscribe to receive this FREE daily commentary directly in your email
[widget id=”wordads_sidebar_widget-41″]
Facebook’s Big Fall, Plus Is Tesla The Next Apple? – The Week Ahead
Earnings will start trickling out this week with companies like Goldman Sachs ($GS), IBM ($IBM) and Procter& Gamble ($PG), but the full slate of earnings don’t start until the week of January 22. So we should just see a continuation of this past week. But one will need to pay close attention to Facebook, Tesla, the Biotech’s, Financials, and Micron.
[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]Â [widget id=”text-11″]Â
[widget id=”text-12″]
The reaction by the stock market to Facebook’s news on Friday seems somewhat dumb because unless I’m missing something, Facebook said the same in 2016. Look at this post I dug up from June 29, 2016, about building a better news feed and putting friends and family first. So either I’m missing something, or the market is missing something. Has your Facebook news feed experience been better since 2016? I’d say I use Facebook even less today then I did then. Every other post in my news feed seems like an ad of some kind, and honestly, I find myself using it less and less, along with LinkedIn. So I think it is smart for Facebook to “make this move,” if anything changes. It could perhaps just be a PR move as well, to get in front of the backlash from all the “fake news” election crap.
Let’s see what happens when Facebook reports results on January 31. I’ll tell you; the stock held support exceptionally well on Friday. I would not be surprised to see the stock back to $188 in a matter of days.
Join our 2,630 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe
Â
Tesla and Apple
Electrek is reporting that the Tesla Model 3 is now starting to hit showrooms, and it is drawing large crowds. The article notes a similarity to the crowds Apple would bring on iPhone launch days. If you are a Tesla shareholder, like I am, you could only dream of the Model 3 having half the success of the iPhone.
Again, it goes to my post many months ago, talking and comparing Tesla and the Model 3, to that of Apple and iPhone. The Model 3, brings the Tesla brand to the ordinary person for the most part, and not just the well to do. It introduces a driver to the Tesla ecosystem, with a network of cars communicating with one another, and artificial intelligence gathering real-time driving miles, helping to make autonomous driving safer. It could be similar to the iPhone and iOS ecosystem, where a person stores photos, or music in the iCloud or iTunes, sends iMessages, and Facetime. When someone buys an iPhone they buy an experience; when someone buys a Model 3, it may come to experience as well.
Or will it come down to brand, just like when you go to get a new phone vs. getting the new iPhone. Will you be getting a new car or the new Tesla? Only through history shall we know the success or failure that is Tesla.
Biotech
Things I’m watching for the week of January 22.
I’m waiting for a biotech breakout on the $IBB at $114 and watching the big Biotech’s Celgene, Biogen, Gilead, and Amgen. Gilead ($GILD) has shown signs of life, and if it cracks $81, I think it will end up rising to around $92.
Celgene
Celgene could see a breakout as well, should it rise above $109, the next stop is likely around $119.
[widget id=”text-13″]
Financials
The $XLF finished the week right at resistance around $29, a level it hasn’t seen in nearly a decade. A rise above $29 sends it higher on towards $31.

Goldman
With Goldman set to report this week, the stock looks ready to rip higher, after bouncing off support around $250. Additionally, the current setup looks like a bullish pennant formation in the chart as well; another sign shares could be set to rise.
Morgan Stanley
Morgan Stanley looks like it could be about to run higher as well. A rise above $56, sends this stock on its way to about $70.
Unlock Deeper Insights with Exclusive Member-Only Video Content on The Market Chronicles YouTube Channel – Just $34.99/Month
[youtube-feed feed=7]
Unlock Deeper Insights with Exclusive Member-Only Video Content on The Market Chronicles YouTube Channel – Just $34.99/Month
[youtube-feed feed=7][widget id=”text-13″]
Micron
Finally, I’m watching Micron this week. The pattern in the chart makes me feel very uneasy.
It just reminds me too much of the chart below.
Let’s hope I’m wrong.
Sorry, but some things you just never forget!
Good Luck this week.
Sign-up for our premium content on Seeking Alpha Market Place – “Reading The Markets” and a get Two Week Free Trial Period
Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments.Â
Now JUST $25 Per Month Or $200 Per Year – Get Your Free 2-Week Trial Now!
Inflation, Tesla Plus So Much More
An Intelligent Way Of Looking At Tesla’s Results
3 Biotech Names To Start The Year
Disney- The Market Finally Get’s It
Free Articles Written By Mike:
Apple Poised to Gain 14%, Defying Skeptics
Gold May Jump Over 20% As Investors Eye Inflation
Roku’s Decline May Be Far From Over As Volatility Surges
Why Under Armour’s Plunge Has Only Begun
Why The FAANGs’ Big Gains May Be Far From Over
How Celgene’s Big Acquisition Could Fire Up Its Stock
Why the Bears Won’t Win at Tesla
Nvidia’s Stock Faces Its Moment of Truth
Why AMD May Rise 17% Higher On Intel’s Woes
Why These 3 Oil Stocks Will Outperform
Why NXP Shareholders Will Prosper Without a Qualcomm Deal
Netflix Breakout Seen Boosting Stock By 17%
We offer daily market commentaries sent directly to your inbox or follow us on Twitter.
Join our 2,630 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe
-OR-
[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]
Michael Kramer and the Clients of Mott Capital own shares of CELG and TSLA
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
© 2017 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Tags: #facebook #tesla #apple #biotech #financials #goldmand #morgan #gilead #celgene
Subscribe to receive this FREE daily commentary directly in your email
This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.